Executive Summary T3 Programme Integrated Clinical Portal

Transcription

1 - L3 Executive Summary T3 Prgramme Integrated Clinical Prtal FINAL Versin N: 2.0 Issue Date: 27 August 2014

2 VERSION CONTROL Versin Date Issued Summary f Change(s) Reviewer s Name(s) /08/14 Updated Patient & Healthcare Gvernance Sandi Carman, Paul Barrett, Kevan Turnbull, Stephen Schuz, Mike Turner /08/14 Updated finance Mike Turner, Kevan Turnbull, Stephen Schuz /08/14 Draft updates and inclusins f cmments T3 Prgramme team senir managers frm the Trust /08/14 Draft updates and inclusin f T3 team cmments Paul Barrett, Infrmatics Assciate Directr Head f Change Delivery Jenny Wilsn, Senir Manager, Strategy & Planning Sandi Carman, Head f Patient and Healthcare Gvernance Mike Turner, T3 Prgramme Manager Kevan Turnbull, T3 ICP Prject Manager Stephen Schuz, T3 Prject Accuntant Bazil Stewart, T3 Business Analyst Kevan Turnbull Stephen Schuz Mike Turner /08/14 Draft Kevan Turnbull Stephen Schuz /08/14 Draft Kevan Turnbull Stephen Schuz

3 REVIEWERS Rle Name Date Medical Directr/Prgramme SRO/Executive Spnsr/Caldictt Guardian Clinical Chief Infrmatin Officer Nursing Directr General Manager Strategy and Planning Deputy Directr Service Imprvement Directr Grup Finance Manager Infrmatics Directr Infrmatics Assciate Directr Head f Change Delivery Head f Service (Infrmatics) HR Deputy Directr Cmmunicatins Directr Learning and Develpment Directr Clinical Safety Officer Patient and Healthcare Gvernance Deputy Finance Directr Interim Chief Operating Officer Head f IT Business Services David Thrssell Rhna Maclean/Karen Selby Helen Brwn/Dtty Watkins Ian Sctt/Ruth Brwn Paul Buckley Becky Jyce Nigel Leek Tracey Sctter Paul Barrett Gregg Duggan Karen Barnard Julie Phelan Linda Crfts David Hughes Sandi Carman Julie Wright Ellen Ryabv Adrian Hart

4 APPROVERS Bard Date T3 Prgramme Bard 20/08/14 Trust Assurance and Planning 21/08/14 Capital Investment Team 01/09/14 Trust Executive Grup 10/09/14 Trust Bard 17/09/14 Fr mre infrmatin n the cntent r status f this dcument, please cntact: Kevan Turnbull

5 EXECUTIVE SUMMARY 1.1 General This business case is spnsred by the Chief Executive at Sheffield Teaching Hspitals (STH) NHS Fundatin Trust. It describes the Integrated Clinical Prtal (ICP) prject, which is ne f three prjects that make up the Transfrmatin Thrugh Technlgy Prgramme (T3). The ther prjects are Electrnic Patient Recrd (EPR) and Electrnic Data Management System (EDMS). The aim f this business case is t secure the required funding and authrisatin t implement an integrated clinical prtal prviding an NHS cmpliant integratin engine, single sign-n fr systems accessibility, and the ability t shw a summarised patient recrd view taken frm multiple clinical systems. 1.2 Scpe The scpe f the prject is t deliver an ICP trust wide t STH. This ICP will deliver 3 main prducts; 1. A cmpliant Integratin Platfrm t meet natinal NHS standards. 2. A Trust wide Single Sign On slutin. 3. A Clinical Prtal delivering a single integrated recrd view f patient infrmatin. 1.3 Weaknesses f the Present Systems There is currently n single system in place that meets the needs f the Trust Clinicians in delivering high quality care. 1.4 Prpsed Slutin The prpsed slutin is t be delivered in 3 phases as fllws: Phase 1 Phase 2 Phase 3 Single Sign On, including: Rle based access cntrls with smartcard access Patient Cnsent cntrls Legitimate Relatinship management cntrls An enhanced Integratin Engine The fllwing cntextual views f the patient recrd, including: A&E/Generic View Cancer View Diabetes View Cmmunity View Integratin with the Lrenz EPR and efrms capability Scial Care Prtal GP Prtal; and

6 Patient Access Since Phase 3, is subject t the utcme f the Trust s bid fr funding frm Rund 2 f the NHS England Integrated Digital Care Technlgy Fund, the utcme f the bid will nt be knwn prir t the required date t award the supplier cntract and therefre it is prpsed t nly undertake phase 1 and 2 at this time. The Technlgy Fund wuld supprt implementatin f phase 3 f the Integrated Clinical Prtal and therefre details have been left in this business case fr infrmatin purpses nly. Refer t Appendix C Phase 3 Overview fr any mre details n this phase. The prpsed slutin will address; IG Cmpliance and auditability NHS Interperability Cmpliance Creatin f single views f patient data which are relevant t the user Sharing f STH data securely within the Trust and the wider Healthcare cmmunity T d this a slutin which cmprises f single sign n, upgrading t an Interperability Tl Kit (ITK) Cmpliant Integratin platfrm and a Clinical Prtal is prpsed fr prcurement. 1.5 Benefits The key benefits fr the ICP can be summarised as: Cmpliance t IG standards fr audit and legitimate relatinships Reduced time t access data systems thrugh the implementatin f a single sign n slutin Reduced time t access patient infrmatin with In cntext patient search facilities Faster decisin making via a single and hlistic view f the patient recrd Imprved patient safety/reduced clinical risk by enabling access t full range f patient infrmatin acrss a number f systems Future prf platfrm t enable Interperability between NHS rganisatins There are mnetary and user benefits assciated with the efficiencies f patient infrmatin searching which has shwn thrugh a recent Trust study t cst clinicians inrdinate amunts f time e.g. Cnsultants acrss A&E spend the equivalent f 301 WTE days per annum searching fr patients acrss their tp 5 systems entering and re-entering patient ID s t find recrds acrss multiple systems. The risk f nn-cmpliance t IG standards and ptential subsequent security breach invlving patient data culd als have serius financial and reputatinal cnsequences fr the Trust. The ICP will imprve the tightening up f IG cmpliance in areas arund access and viewing f patient data. The biggest benefit, hwever, is t the patient, by virtue f the treating clinician having easy and quick access t their infrmatin thrugh the clinical prtal, irrespective f the surce f the riginal data.

7 1.6 Csts The csts f the prject ver 8 years are detailed belw. The prject has been split int 3 phases as stated. Fr the purpses f the cstings and driving t a recmmendatin, Phases 1 & 2 have been cmbined and are included belw. Phases 1 & 2; The capital csts are 8,141,239 The nn-recurrent revenue csts are 1,417,025 The recurrent revenue csts excluding capital charges are 3,490,705 The lifecycle capital charges are 8,526,509 All figures include VAT, where applicable. Fllwing gd accunting practice, included in the capital and revenue figures (abve) is a risk and cntingency value f 2,133,478. Benefits t the value f 60m have been identified, f which 10m are cash-releasing. This makes the prject self-funding ver the 8 year prject lifecycle. Taking int accunt the csts and benefits detailed, the Return-On-Investment is Phase 3 Appendix C cntains the details fr Phase 3 (fr infrmatin nly). 1.7 Timescales Subject t gverning apprval f the recmmendatins in this business case, and the develpment f the jint supplier/trust PID, the implementatin f this prject is expected t start in Octber Early apprval is essential t ensure that the prcurement exercise is cmpleted within the mandated framewrk timescales Phase 1 runs frm Octber thrugh t March 2015 and implements the Single Sign On (SSO), Integratin wrk, and IG cntrls that wuld enable a Clinical Prtal t be delivered Phase 2 delivers the initial clinical prtal views Trust wide rllut cmmencing May 2015 Further details are utlined in Appendix B The Integrated Clinical Prtal Prject Radmap. 1.8 Risks The fllwing verarching risks have been identified: Failure t apprve this business case and award the cntract prir t September 16th 2014 will mean a 3-6 mnth re-prcurement at an estimated Trust expense f 300,000. STH are unsuccessful in their Integrated Digital Care Fund bid. This wuld remve the pssibility f ICP phase 3 and challenge the achievement f the Health Ecnmy wide Integrated Digital Care Recrd. The degree f rganisatinal readiness required fr business change is nt fully implemented as the ICP ges live. This culd result in lack f user engagement in the ICP, a prlnged rll-ut, scpe creep, and ultimately delays t benefits realisatin and ultimately perfrmance dip in the services impacted.

8 Training is nt effectively r fully implemented as the ICP ges live due t the scale and cmplexity f the required training mdel being underestimated. It is intended t crdinate training with EDMS due t bth prjects sharing similar rlluts. Hwever, if either EDMS r ICP run late this wuld increase csts due t cnducting training in 2 sessins (ne fr EDMS and ne fr ICP) instead f jint training sessins which culd be achieved in mst circumstances. Any technical dependencies identified pst FBC (full business case) which may ccur assciated with the integratin and interperability leading t extra wrk required t bring the Integratin Platfrm up t cmpliance level bth technically and frm a NHS Standards cmpliance (ITK) perspective fr CP delivery. This again culd result in a prlnged rll-ut, increase in csts due t making current interfaces cmpliant and ultimately delays t benefits realisatin. The values attributed t the benefits are nt realised. This wuld result in a failure t deliver return f investment as planned. Failure t deliver a slutin that meets clinical requirements. In phase 1 a key activity is design f clinical views with clinical input. There is a risk clinicians will nt be able t release time needed t design their views thus impact n the delivered clinical view. As the ICP is rlled ut its success may mean reliance n the system exceeds current expectatins. In such circumstances shuld there be technical issues then the supprt functin may nt be sufficient t supprting users particularly ut f hurs. Assuming the recmmendatin is apprved t cntinue with Phase 1 and 2, the verall risk and cntingency has been identified f 2,133, Cnclusins The investment in an ICP is essential fr STH t help it achieve its visin fr an integrated digital care recrd t supprt; imprving patient care and safety, and the patient experience, in additin t maximising the prductivity and efficiency f STH Recmmendatins The recmmendatins therefre are as fllws: Apprve this Business Case t award the cntract t the preferred bidder fr the first tw phases. Apprve the funding f the capital csts f Phase 1 and 2 at 8,141,239 Fund the assciated nn-recurrent revenue csts f 1,417,025 Fund the assciated recurrent revenue csts f 3,490,705 Fund the assciated lifecycle capital charges f 8,526,509 Use the benefits f 60,000,000 t ffset this cst Await the annuncement f the NHS England funding befre re-presenting the business case fr Phase 3 the csts f which are highlighted in Appendix C (fr infrmatin purpses nly).